Eli Chapman

Research Focus Group Membership: 
Research Focus Group 3

BS Chemistry, University of California at Berkeley, 1996
MA Chemistry, Columbia University, N.Y., 1998
PhD Chemistry, Scripps Research Institute, La Jolla, Calif., 2003

College Affiliations: 

College of Pharmacy

Research Interests: 

The effects of chronic arsenic exposure on protein quality control and how this relates to disease development and progression.

Environmental Health Research & Expertise: 

Dr. Chapman has had training in organic chemistry, protein biochemistry, enzymology, molecular biology, and genetics. His present independent research program is in the Drug Discovery and Development track in the Department of Pharmacology and Toxicology and is populated with students interested in the hunt for modulators of protein function and the detailed study of such interactions. In particular, his lab is interested in the development of methods to discover modulators of enzymes that are challenging to drug or proteins that are not enzymes and are thus considered “undruggable”. In these efforts, they use contemporary molecular biology and biochemistry techniques.

In a collaboration with Dr. Jonathan Schatz, a former member of the University of Arizona Cancer Center, they have recently discovered a natural product, elatol, from algae that is an inhibitor of the DEAD Box RNA helicase, eIF4A, which is essential for cap-dependent translation. They have shown, in cellular models, that this compound is effective at killing B-cell lymphoma cells. More recently, they have isolated sufficient materials to initiate in vivo studies. In addition, they have discovered a collective of inhibitors targeting the AAA+ chaperone, p97, which is an integral pert of protein quality control. Their studies and those of other groups including a recent clinical trial, indicate p97 is a viable target for a variety of cancers

Select Publications


Tao, S., S. Wang, S. Javad Moghaddam, A. Ooi, E. Chapman, P. K. Wong, and D. D. Zhang, "Oncogenic KRAS confers chemoresistance by upregulating NRF2.", Cancer Res, vol. 74, issue 24, pp. 7430-41, 2014 Dec 15. PubMed PMCID: PMC4268230  PMID: 25339352
Wu, T., F. Zhao, B. Gao, C. Tan, N. Yagishita, T. Nakajima, P. K. Wong, E. Chapman, D. Fang, and D. D. Zhang, "Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis.", Genes Dev, vol. 28, issue 7, pp. 708-22, 2014 Apr 1. PubMed PMCID: PMC4015486  PMID: 24636985